Finanzwire Finanzwire
Basculer en Français
10411 Companies
217801 Keywords
147354 Articles
115246 Press releases
Headlines Articles Press releases MAbxience Remove
  1. Home
  2. Companies
  3. MAbxience
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 12/22/2025 at 22:10, 4 months 24 days ago

    FDA Approves mAbxience and Amneal's Denosumab Biosimilars

    FDA Approval Amneal Pharmaceuticals Denosumab Biosimilars MAbxience Affordable Biologics
  • PRESS RELEASE

    published on 12/22/2025 at 22:05, 4 months 24 days ago

    mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

    mAbxience and Amneal announced FDA approval of denosumab biosimilars referencing Prolia and XGEVA, expanding affordable biologic access in the US
    FDA Approval Denosumab Biosimilars MAbxience Amneal Prolia XGEVA
    Logo of MAbxience
  • BRIEF

    published on 12/04/2025 at 09:10, 5 months 11 days ago

    MAbxience and HP Collaborate on AI in Biomanufacturing

    Artificial Intelligence Biosimilars Biomanufacturing MAbxience HP Inc.
  • PRESS RELEASE

    published on 12/04/2025 at 09:05, 5 months 11 days ago

    mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development

    mAbxience and HP collaborate on AI solution to optimize biomanufacturing and biosimilar development, enhancing predictability and efficiency. Project aims to improve patient access to biologic therapies
    AI Solution Biosimilar Development Biomanufacturing MAbxience HP
    Logo of MAbxience
Accesswire
  • Published on 05/15/2026 at 23:10, 34 minutes ago

    Golden Minerals Reports First Quarter 2026 Financial Results

  • Published on 05/15/2026 at 23:00, 44 minutes ago

    Jericho Energy Ventures Announces Transition to Semi-Annual Reporting to Enhance Efficiency

  • Published on 05/15/2026 at 18:45, 4 hours 59 minutes ago

    HELLENiQ ENERGY Holdings S.A. Announces First Quarter 2026 Financial Results

  • Published on 05/15/2026 at 14:35, 9 hours 9 minutes ago

    NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

  • Published on 05/15/2026 at 14:30, 9 hours 14 minutes ago

    AIAI Holdings Corporation Expresses Appreciation to Revere Securities for Financial Advisory Support on Successful NASDAQ Direct Listing

View all ACCESSWIRE
EQS Group
  • Published on 05/15/2026 at 20:10, 3 hours 34 minutes ago

    CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement

  • Published on 05/15/2026 at 18:30, 5 hours 14 minutes ago

    Designated Person Notifications

  • Published on 05/15/2026 at 18:10, 5 hours 34 minutes ago

    Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success

  • Published on 05/15/2026 at 17:33, 6 hours 11 minutes ago

    Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio

  • Published on 05/15/2026 at 16:48, 6 hours 56 minutes ago

    Fuller, Smith & Turner PLC: Transaction in own shares

View all EQS
Les Echos
  • Published on 05/15/2026 at 15:08, 8 hours 36 minutes ago

    Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026

  • Published on 05/13/2026 at 18:00, 2 days 5 hours ago

    DDV monthly statement at April 30 2026

  • Published on 05/13/2026 at 17:45, 2 days 5 hours ago

    Infotel confirms its return to growth in Q1 2026 with revenue up 8.6%. Proposed dividend of €2 per share for 2025.

  • Published on 05/13/2026 at 17:45, 2 days 5 hours ago

    Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2026

  • Published on 05/13/2026 at 17:40, 2 days 6 hours ago

    Report on share repurchases from 6 to 12 May 2026

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy